Midatech Pharma PLC Grant of Options and PDMR dealings (3774F)
15 Julio 2021 - 4:28AM
UK Regulatory
TIDMMTPH
RNS Number : 3774F
Midatech Pharma PLC
15 July 2021
15 July 2021
Midatech Pharma PLC
("Midatech" or the "Company")
Grant of Options
PDMR dealings
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery
technology company focused on improving the bio-delivery and
bio-distribution of medicines announces that options over a total
of 1,924,000 ordinary shares of 0.1 pence each in the capital
Company have been granted to employees under the 2014 Midatech
Pharma plc Enterprise Management Incentive Scheme ("Options").
Of these Options, 750,000 in aggregate have been granted to two
executives designated as PDMRs; Stephen Stamp, Chief Executive
Officer, Chief Financial Officer and director of the Company and
Dmitry Zamoryakhin, Chief Scientific Officer resulting in them
having the following interests in the Company:
Director Award of Options Resulting interest Current shareholding
in options in the Company
Stephen Stamp -
Chief Executive
Officer, Chief
Financial Officer 500,000 830,000 50,000
Dmitry Zamoryakhin
- Chief Scientific
Officer 250,000 250,000 -
The Options have an exercise price of 27.75 pence per share,
being the mid-market closing price on 14 July 2021. The Options
will vest 25% upon the one year anniversary of grant, with the
remainder vesting in 12 equal tranches quarterly over the following
three years. Once vested, the options will be exercisable until 14
June 2031.
The Options granted represent 1.95 per cent. of the issued share
capital.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Stephen Stamp
------------------------------------- ----------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------------------
a) Position/status Chief Executive Officer, Chief Financial
Officer
------------------------------------- ----------------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------- ----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------------------
a) Name Midatech Pharma plc
------------------------------------- ----------------------------------------------
b) LEI 549300GKR2G40H3QFY57
------------------------------------- ----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------------------
a) Description of the Options over Ordinary shares of 0.1
financial instrument, pence each in Midatech Pharma plc
type of instrument
Identification code GB00BKT14T00
b) Nature of the transaction Grant of Options over Ordinary shares
------------------------------------- ----------------------------------------------
c) Price(s) and volume(s)
--------------------- --------------------
Price(s) Volume(s)
--------------------- --------------------
27.75p 500,000
--------------------- --------------------
d) Aggregated information
- Aggregated volume As above
- Price
e) Date of the transaction 15 June 2021
------------------------------------- ----------------------------------------------
f) Place of the transaction Off market transaction
------------------------------------- ----------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dmitry Zamoryakhin
------------------------------------- -------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------
a) Position/status Chief Scientific Officer
------------------------------------- -------------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------- -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------------
a) Name Midatech Pharma plc
------------------------------------- -------------------------------------------
b) LEI 549300GKR2G40H3QFY57
------------------------------------- -------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------------
a) Description of the Options over Ordinary shares of 0.1
financial instrument, pence each in Midatech Pharma plc
type of instrument
Identification code GB00BKT14T00
b) Nature of the transaction Grant of Options over Ordinary shares
------------------------------------- -------------------------------------------
c) Price(s) and volume(s)
------------------- -------------------
Price(s) Volume(s)
------------------- -------------------
27.75 p 250,000
------------------- -------------------
d) Aggregated information
- Aggregated volume As above
- Price
e) Date of the transaction 15 June 2021
------------------------------------- -------------------------------------------
f) Place of the transaction Off market transaction
------------------------------------- -------------------------------------------
For more information, please contact:
Midatech Pharma PLC
Stephen Stamp, CEO, CFO
Tel: +44 (0)29 2048 0180
www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated Adviser and Joint
Broker)
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Tel: +44 (0)20 7886 2500
Turner Pope Investments (TPI) Limited (Joint Broker)
Andrew Thacker / James Pope (Corporate Broking)
Tel: +44(0)20 3657 0050
IFC Advisory Limited (Financial PR and UK Investor Relations)
Tim Metcalfe / Graham Herring
Tel: +44 (0)20 3934 6630
Email: midatech@investor-focus.co.uk
Edison Group (US Investor Relations)
Maxwell Colbert
Tel: +1 (646) 653 7028
Email: mcolbert @edisongroup.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHSFWSUIEFSEEW
(END) Dow Jones Newswires
July 15, 2021 05:28 ET (09:28 GMT)
Midatech Pharma (LSE:MTPH)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Midatech Pharma (LSE:MTPH)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
